Call for Abstracts

We invite you to participate in the Call for Abstracts for the 27th Annual Meeting of the American Society of Breast Surgeons. The meeting will be held at the Seattle Convention Center in Seattle, WA, from April 29–May 3, 2026. Review the guidelines below for helpful information on preparing and submitting your abstract. If you have any questions, please contact abstracts@breastsurgeons.org or call us at 877-992-5470 or 410-381-9500.

All abstracts must be submitted through our abstract submission portal no later than 3:00 AM ET / 12:00 AM PT on November 6, 2025. Authors may submit 1 or more abstracts for consideration for presentation. Each abstract submission is subject to a nonrefundable $60 submission fee.

Click Here to access the abstract submission portal.

Instructions for Abstract Submission

Abstracts must not contain data that have been previously presented or will be presented or published prior to ASBrS 2026. Institutional names must not be included anywhere in the title or body of the abstract. Case reports will not be accepted. Submissions are subject to a character limit — 4000 characters for the background, methods, objectives, and results. Titles are limited to 180 characters. Authors are not included in the character limit. Submissions may include no more than 1 table or figure. All words must be those of the authors: abstracts written by artificial intelligence (AI) will not be accepted. All abstracts must be submitted through the abstract submission portal.

Author Disclosure Policy

ASBrS promotes balance, independence, objectivity, and scientific rigor in all of its educational activities through the disclosure of financial or non-financial/strategic business relationships or partnerships (relationships) and mitigation of relevant relationships. The relationships requiring disclosure are outlined in the ASBrS CME Activity Disclosure Policy. All authors are required to disclose all financial, and non-financial/strategic, business relationships or partnerships (relationships) with any ineligible company they have had over the past 24 months.

Companies that are ineligible to be accredited in the ACCME System are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. If the first presenting author is employed by an ineligible company as defined by the ACCME and does not meet the limited circumstances outlined in Standard 3.2., an alternate presenter who does not have a relevant employment relationship must be named if the abstract is selected for presentation in an oral abstract session. Oral abstract presenters will also be subject to the same disclosure review and management strategies as faculty. The alternate presenter should not be financially motivated or interested in presenting the abstract.

Disclosure Mitigation

All oral abstract presenters will also be subject to the disclosure review and mitigation process outlined in the 'CME Activity Disclosure Process for Financial or Non-financial/Strategic Business Relationships or Partnerships'. Oral abstract presenters must disclose all financial, and non-financial/strategic, business relationships or partnerships (relationships) with any ineligible company they have had over the past 24 months. Financial relationships of any dollar amount or non-financial/strategic business relationships or partnerships are defined as relevant if the educational content is related to the business lines or products of the ineligible company.

Should it be determined that a relevant relationship exists, the individual will be contacted by a designated ASBrS official with methods to mitigate the relationship. An advanced conflict mitigation process will be initiated if the designated ASBrS official determines a relevant relationship requires additional review. The CME committee will determine the applicable parties for additional review. If the relevant relationship cannot be mitigated, an alternate presenter must be named and will be subject to the 'CME Activity Disclosure Process for Financial or Non-financial/Strategic Business Relationships or Partnerships'. All relevant relationships must be mitigated before the start of ASBrS 2026.

Abstract Review Criteria

The background is a clear and concise overview of the objective of the study. A specific, clear, and testable hypothesis is stated. The methods provide a clear explanation of the experimental design and analysis. The results are presented clearly and follow logically from the stated purpose/hypothesis of the study. The results provide findings (data) without interpretation of the results. The conclusion (interpretation of data) is supported by the results provided.The rationale for the significance and importance of the work is presented as a well-structured, logical argument. Ideally, the abstract is clinically relevant and likely to generate discussion by the membership, be cited when published and/or lead to additional studies.

Special Submission Categories

Early International Poster Track

International authors have two submission options: (1) Submit to this early-deadline poster track by October 5, or (2) Submit to the regular abstract categories (including oral presentations) by the November 6 deadline. Abstracts submitted in this category must be submitted by October 5, 2025, to be considered for early review. Decision letters will be emailed to submitters by the end of October 2025. Abstracts submitted in this category must be from outside the US and Canada and will be considered for poster presentation only. Authors of accepted abstracts can receive a letter from the ASBrS for visa application, if needed, to attend the ASBrS 2026 meeting. All abstract submissions in this category also are subject to a non-refundable $60 submission fee.

Current Accruing Prospective Clinical Trials Abstracts

Abstracts submitted in this category should describe the primary and secondary objectives of the trials, targeted accrual, sites the trial is open at, date of activation, anticipated study length, and trial design. Abstracts submitted to this category will be considered for poster presentation only.

Late Breaking Abstracts

Late Breaking Abstract submission will open after the regular abstract November 6, 2025 deadline. The deadline for submission of late breaking abstracts is 3:00 AM ET / 12:00 AM PT on January 9, 2026. The ASBrS will accept late breaking abstracts specifically reporting from prospective clinical trials FOR WHICH PATIENTS SIGNED INFORMED CONSENT PRIOR TO PARTICIPATION. Abstracts from other types of studies will not be considered in this category. Late breaking abstracts must include the final study results. Abstracts not reporting results, e.g. stating that the data will be presented (but is not within the abstract) are ineligible. Submitters will be notified of the abstract decisions by email in January 2026.

Presentation Types

All abstracts will be reviewed by the ASBrS Annual Meeting Scientific Committee. Presentation dates are tentative and subject to change. The top abstracts will be selected for 1 of the following presentation formats:

• Oral: Each presenter will be given 6 minutes for their presentation, followed by 2–3 minutes for questions. In order to be eligible for acceptance, you must have an author who will be available to present during the assigned session.
• Quick Shot: Each presenter will be given 3 minutes for their presentation, which will be followed by a 2-minute discussion period. In order to be eligible for acceptance, you must have an author who will be available to present during this session.
• Poster: The Scientific Poster Session and Reception will be held on Friday, May 1, 2026. Your abstract's presenter must be available to discuss the poster with interested meeting attendees during this session. ASBrS will provide thumbtacks and an 8-foot-wide by 4-foot-high carpeted, framed board on which to mount your poster.

Opportunities for Publication

Accepted abstracts will be published online in Annals of Surgical Oncology. Authors of abstracts accepted for oral presentations, quick shot presentations, and select poster presentations will be invited to submit a manuscript for possible publication in the October 2026 issue of Annals of Surgical Oncology. Manuscript submission is required to be eligible for the George Peters Award and Scientific Presentation Award. All manuscripts must be submitted by April 22, 2026. No extensions will be given.

Special Awards

The George Peters Award

Breast fellows presenting an oral or quick shot presentation will be considered for the George Peters Award. To be eligible, a manuscript must be submitted to Annals of Surgical Oncology by April 22, 2026. This award was established by ASBrS to honor Dr. George N. Peters, who was instrumental in bringing together ASBrS with the Susan G. Komen Breast Cancer Foundation, the American Society of Breast Disease, and the Society of Surgical Oncology for the development of educational objectives for breast fellowships. The educational objectives were first used to award Komen Interdisciplinary Breast Fellowships. Subsequently, the curriculum was used for the breast fellowship credentialing process that has led to the development of a nationwide matching program for breast fellowships. The award winner will be granted a prize of $1000.

The Scientific Presentation Award

Medical students, residents, and fellows presenting an oral or quick shot presentation will be considered for the Scientific Presentation Award. To be eligible, a manuscript must be submitted to Annals of Surgical Oncology by April 22, 2026. The award winner will be granted a prize of $500.

Scientific Impact Award

All oral presentations will be considered for the Scientific Impact Award for the best paper as voted by the audience. The winner receives a plaque.

CME Clinical Content Validation